论文部分内容阅读
目的探讨胸苷磷酸化酶(TP)在肿瘤细胞中的表达及与卡培他滨临床疗效之间的关系。方法33例恶性肿瘤患者(乳腺癌12例,结直肠癌21例)均用过卡培他滨治疗并有临床评价,用免疫组化方法回顾性检测患者治疗前肿瘤组织石蜡标本中胸苷磷酸化酶的表达,比较卡培他滨临床疗效与肿瘤细胞中TP表达阳性率之间的关系。结果乳腺癌TP阳性率83.3%(10/12);结、直肠癌TP阳性率57.2%(12/21)。卡培他滨在乳腺癌和结、直肠癌患者中总的疾病控制率(CR+PR+NC)为63.6%(21/33),其中在TP阳性患者中的疾病控制率为81.8%(18/22),在TP阴性患者中的疾病控制率为27.3%(3/11),二者差异极显著(P<0.01)。结论在乳腺癌和结直肠癌患者中,TP阳性表达的患者对卡培他滨反应更好,疗效更高。为TP表达作为卡培他滨疗效的预测指标提供理论依据。
Objective To investigate the expression of thymidine phosphorylase (TP) in tumor cells and its relationship with the clinical efficacy of capecitabine. Methods Thirty-three patients with malignant tumor (12 cases of breast cancer and 21 cases of colorectal cancer) were treated with capecitabine and evaluated clinically. Immunohistochemistry was used to detect the expression of thymidine phosphate The relationship between the clinical efficacy of capecitabine and the positive rate of TP expression in tumor cells was compared. Results The positive rate of TP in breast cancer was 83.3% (10/12). The positive rate of TP in node and rectum cancer was 57.2% (12/21). The overall rate of disease control (CR + PR + NC) was 63.6% (21/33) for capecitabine in patients with breast cancer and in patients with colorectal cancer, with a disease control rate of 81.8% (18/18) in TP-positive patients / 22). The rate of disease control in TP-negative patients was 27.3% (3/11), the difference was significant (P <0.01). Conclusion In patients with breast cancer and colorectal cancer, patients with positive TP expression responded better to capecitabine and had higher efficacy. Provide a theoretical basis for TP expression as a predictor of capecitabine efficacy.